WO1997036588A3 - Use of 1,1-dialkyl-1,2,3,4-tetrahydroisoquinolines for the manufacture of a medicament for the treatment of psychosis and pain - Google Patents

Use of 1,1-dialkyl-1,2,3,4-tetrahydroisoquinolines for the manufacture of a medicament for the treatment of psychosis and pain Download PDF

Info

Publication number
WO1997036588A3
WO1997036588A3 PCT/JP1997/001062 JP9701062W WO9736588A3 WO 1997036588 A3 WO1997036588 A3 WO 1997036588A3 JP 9701062 W JP9701062 W JP 9701062W WO 9736588 A3 WO9736588 A3 WO 9736588A3
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydroisoquinolines
dialkyl
psychosis
pain
medicament
Prior art date
Application number
PCT/JP1997/001062
Other languages
French (fr)
Other versions
WO1997036588A2 (en
Inventor
Masaaki Hirobe
Shigeru Ohta
Yoshikazu Masukawa
Original Assignee
Lederle Japan Ltd
Masaaki Hirobe
Shigeru Ohta
Yoshikazu Masukawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lederle Japan Ltd, Masaaki Hirobe, Shigeru Ohta, Yoshikazu Masukawa filed Critical Lederle Japan Ltd
Priority to JP9535125A priority Critical patent/JP2000507569A/en
Priority to AU21765/97A priority patent/AU2176597A/en
Publication of WO1997036588A2 publication Critical patent/WO1997036588A2/en
Publication of WO1997036588A3 publication Critical patent/WO1997036588A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Antipsychotics and analgesics containing 1,1-dialkyl-1,2,3,4-tetrahydroisoquinolines represented by formula (I) wherein R?1 and R2¿ are, independently each other, lower alkyl groups, or pharmaceutically acceptable salts thereof, which exert a potent antipsychotic effect by blocking dopamine D¿2? receptors and also a potent analgesic effect without causing any morphine-like dependence.
PCT/JP1997/001062 1996-03-29 1997-03-28 Use of 1,1-dialkyl-1,2,3,4-tetrahydroisoquinolines for the manufacture of a medicament for the treatment of psychosis and pain WO1997036588A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP9535125A JP2000507569A (en) 1996-03-29 1997-03-28 Use of 1,1-dialkyl-1,2,3,4-tetrahydroisoquinoline for producing antipsychotics and analgesics
AU21765/97A AU2176597A (en) 1996-03-29 1997-03-28 Use of 1,1-dialkyl-1,2,3,4-tetrahydroisoquinolines for the manufacture of a medicament for the treatment of psychosis and pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8/99666 1996-03-29
JP9966696 1996-03-29

Publications (2)

Publication Number Publication Date
WO1997036588A2 WO1997036588A2 (en) 1997-10-09
WO1997036588A3 true WO1997036588A3 (en) 1997-12-24

Family

ID=14253366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/001062 WO1997036588A2 (en) 1996-03-29 1997-03-28 Use of 1,1-dialkyl-1,2,3,4-tetrahydroisoquinolines for the manufacture of a medicament for the treatment of psychosis and pain

Country Status (3)

Country Link
JP (1) JP2000507569A (en)
AU (1) AU2176597A (en)
WO (1) WO1997036588A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013073A1 (en) * 1991-12-23 1993-07-08 The Boots Company Plc Substituted tetrahydroisoquinolines and their use as therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013073A1 (en) * 1991-12-23 1993-07-08 The Boots Company Plc Substituted tetrahydroisoquinolines and their use as therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MITSURU OKHUBO ET AL.: "Studies on cerebral protective agnets. IX. Synthesis of novel 1,2,3,4-tetrahydroisoquinolines as N-Methyl-D-aspartate antagonists", CHEM. PHARM. BULL., vol. 44, no. 1, January 1996 (1996-01-01), pages 95 - 102, XP000652252 *

Also Published As

Publication number Publication date
WO1997036588A2 (en) 1997-10-09
AU2176597A (en) 1997-10-22
JP2000507569A (en) 2000-06-20

Similar Documents

Publication Publication Date Title
EP0663401A4 (en) Morphinan derivative and medicinal use.
EP1310488A4 (en) Fused bicyclic amide compounds and medicinal use thereof
SI0937041T1 (en) Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament
CA2228249A1 (en) Pain-alleviating drug composition and method for alleviating pain
MY115662A (en) Novel compounds with analgesic effect
UA72881C2 (en) Thienopyrimidine and derivatives of thienopyrimidine as anticancer agents
MY132705A (en) Novel compounds with analgesic effect
MY119403A (en) Novel compounds with analgesic effect.
WO1999012532A3 (en) Piperidine derivatives against malaria
ID24487A (en) COMPOUND, BENZOSIKLOHEPTATIOFEN COMPOUNDS
EP0781561A4 (en) Novel medicinal use of 5ht 3? antagonist
AU2003239389A1 (en) Opioid receptor antagonists
WO1999009025A3 (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor
ES2128043T3 (en) USE OF BIS (AMIDINOBENCIMIDAZOLES) IN THE PREPARATION OF A MEDICINAL PRODUCT TO INHIBIT RETROVIRAL INTEGRASE.
AU1549500A (en) Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
WO1996005166A1 (en) Substituted amine derivative and medicinal composition containing the same
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
MX9800620A (en) (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-y l)-2-methoxy-6-methylamino-3-pyridine-carboxamide, process for producing the same and medicinal composition containing the same.
WO1997036588A3 (en) Use of 1,1-dialkyl-1,2,3,4-tetrahydroisoquinolines for the manufacture of a medicament for the treatment of psychosis and pain
ES2149193T3 (en) HETEROCICLIC COMPOUNDS REPLACED WITH RENT.
HU9801792D0 (en) 4-aminopyrrole(3,2-d)pyrimidines as neuropeptide y receptor antagonists
WO2002024661A3 (en) New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
AU2002214657A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
IE891261L (en) Heterotetracyclic lactam derivatives
ZA911452B (en) New use of 5-(2-(tert-butylamino)-1-hydroxyethyl)-m-phenylene-bis(dimethylcarbanate)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA HU IL JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase